ArticleNPJ biofilms and microbiomes2025
Harnessing machine learning to predict antibiotic susceptibility in Pseudomonas aeruginosa biofilms.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Antibacterial and antibiofilm effects of natural phenolic acids: Insights into structure-function relationships, extracellular pH, and morphological changes.Microbiology spectrum · 2026Article
- Experimental evolution reveals adaptive pathways to reduced antibiotic susceptibility inMicrobiology (Reading, England) · 2026Article
- UnderstandingMicroorganisms · 2026Review
- Antibiotic resistance inFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Antibiotic susceptibility tests (ASTs) often fail to predict treatment outcomes because they do not account for biofilm-specific tolerance mechanisms. In the present study, we explored alternative approaches to predict tobramycin susceptibility of Pseudomonas aeruginosa biofilms that were experimentally evolved in physiologically relevant conditions. To this end, we used four analytical methods - whole-genome sequencing (WGS), matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), isothermal microcalorimetry (IMC) and multi-excitation Raman spectroscopy (MX-Raman). Machine learning models were trained on data outputs from these methods to predict tobramycin susceptibility of our evolved strains and validated with a collection of clinical isolates. For minimal inhibitory concentration (MIC) predictions of the evolved strains, the highest accuracy was achieved with MALDI-TOF MS (97.83%), while for biofilm prevention concentration (BPC) predictions, Raman spectroscopy performed best with an accuracy of 80.43%. Overall, all analytical methods demonstrated comparable predictive performance, showing their potential for improving biofilm AST.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.